» Articles » PMID: 35393318

Defining Timeliness in Care for Patients with Lung Cancer: a Scoping Review

Overview
Journal BMJ Open
Specialty General Medicine
Date 2022 Apr 8
PMID 35393318
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Early diagnosis and reducing the time taken to achieve each step of lung cancer care is essential. This scoping review aimed to examine time points and intervals used to measure timeliness and to critically assess how they are defined by existing studies of the care seeking pathway for lung cancer.

Methods: This scoping review was guided by the methodological framework for scoping reviews by Arksey and O'Malley. MEDLINE, EMBASE, CINAHL and PsycINFO electronic databases were searched for articles published between 1999 and 2019. After duplicate removal, all publications went through title and abstract screening followed by full text review and inclusion of articles in the review against the selection criteria. A narrative synthesis describes the time points, intervals and measurement guidelines used by the included articles.

Results: A total of 2113 articles were identified from the initial search. Finally, 68 articles were included for data charting process. Eight time points and 14 intervals were identified as the most common events researched by the articles. Eighteen different lung cancer care guidelines were used to benchmark intervals in the included articles; all were developed in Western countries. The British Thoracic Society guideline was the most frequently used guideline (20%). Western guidelines were used by the studies in Asian countries despite differences in the health system structure.

Conclusion: This review identified substantial variations in definitions of some of the intervals used to describe timeliness of care for lung cancer. The differences in healthcare delivery systems of Asian and Western countries, and between high-income countries and low-income-middle-income countries may suggest different sets of time points and intervals need to be developed.

Citing Articles

Evaluating the Time Interval Between Symptoms Onset, Diagnosis, and Therapeutic Intervention in Lung Cancer: A Cross-Sectional Study in Southern Iran.

Salehi A, Rezvani A, Fallahi M, Gholamabbas G, Moayedfar M Cancer Rep (Hoboken). 2024; 7(10):e70026.

PMID: 39423347 PMC: 11488750. DOI: 10.1002/cnr2.70026.

References
1.
Helsper C, van Erp N, Peeters P, de Wit N . Time to diagnosis and treatment for cancer patients in the Netherlands: Room for improvement?. Eur J Cancer. 2017; 87:113-121. DOI: 10.1016/j.ejca.2017.10.003. View

2.
Maiga A, Deppen S, Pinkerman R, Callaway-Lane C, Massion P, Dittus R . Timeliness of Care and Lung Cancer Tumor-Stage Progression: How Long Can We Wait?. Ann Thorac Surg. 2017; 104(6):1791-1797. PMC: 5813822. DOI: 10.1016/j.athoracsur.2017.06.051. View

3.
Vidaver R, Shershneva M, Hetzel S, Holden T, Campbell T . Typical Time to Treatment of Patients With Lung Cancer in a Multisite, US-Based Study. J Oncol Pract. 2016; 12(6):e643-53. DOI: 10.1200/JOP.2015.009605. View

4.
Arnold M, Rutherford M, Bardot A, Ferlay J, Andersson T, Myklebust T . Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019; 20(11):1493-1505. PMC: 6838671. DOI: 10.1016/S1470-2045(19)30456-5. View

5.
Rolke H, Bakke P, Gallefoss F . Delays in the diagnostic pathways for primary pulmonary carcinoma in Southern Norway. Respir Med. 2006; 101(6):1251-7. DOI: 10.1016/j.rmed.2006.10.021. View